GlassScriptPhysician profile
Fares Diarbakerli
NPI 1508011602
$7,955.83
in general payments reported to CMS, 2019-2025
26 companies · $483 in 2025
The $483 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $225 · 2021: $211 · 2022: $2,806 · 2023: $3,888 · 2024: $13.75 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,300 · Education: $1,500 · Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,300.00 |
| Education | $1,500.00 |
| Food and Beverage | $585.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,175.14 | 2022-2023 | Davinci Xi |
| Flexdex INC. | $2,300.00 | 2023 | |
| Ethicon US, LLC | $274.94 | 2019-2025 | Megadyne, Enseal |
| Hologic Sales and Service, LLC | $252.64 | 2021-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System |
| Abbvie INC. | $234.09 | 2019-2022 | |
| Exeltis, USA INC. | $102.64 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $80.33 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $61.12 | 2019-2020 | |
| Mission Pharmacal Company | $45.84 | 2019 | |
| Merck Sharp & Dohme LLC | $43.53 | 2019 | |
| Avion Pharmaceuticals | $38.59 | 2019-2021 | |
| Myovant Sciences INC. | $31.69 | 2021-2022 | |
| Dysis Medical, INC. | $29.63 | 2021-2022 | |
| Olympus America INC. | $29.55 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $29.08 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $29.00 | 2020 | |
| Mayne Pharma Commercial LLC | $27.77 | 2021-2022 | |
| Allergan, INC. | $26.79 | 2019-2020 | |
| Lupin INC. | $26.75 | 2019 | |
| Mimedx Group, INC. | $23.82 | 2025 | |
| Roche Diagnostics Corporation | $21.04 | 2020 | |
| Medtronic, INC. | $15.13 | 2021 | |
| Medicem INC. | $14.55 | 2021 | |
| Teleflex LLC | $14.24 | 2020 | |
| Astellas Pharma US INC | $14.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.75 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fares Diarbakerli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.